Antag Therapeutics

Therapeutic peptides for the modulation of GIP biology

Antag Therapeutics is a preclinical stage biotechnology company committed to the development of novel therapeutic peptides for metabolic – and cardiovascular autonomic diseases.

Antag Therapeutics is based on decades of research from the University of Copenhagen focusing on understanding and targeting incretin physiology. Our therapeutic peptides are based on a novel endogenous peptide antagonist discovered by the research teams of Professors Jens Juul Holst and Mette Rosenkilde that has been characterized in several human intervention studies.

Focus area

Postural orthostatic tachycardia syndrome (POTS)

POTS affects 3 million people in the US, predominantly females of child-bearing age, and is characterized by orthostatic intolerance and tachycardia. Patients have reduced quality of life similar to living with chronic obstructive pulmonary disease and congestive heart failure. Unfortunately, there are no approved medications for POTS, so patients rely on ineffective off-label pharmacological and nonpharmacological treatments.


According to WHO, more than 650 million people worldwide suffer from obesity, and the number increases every year. Obesity leads to comorbidities such as type 2 diabetes, fatty liver disease, stroke, coronary artery disease, cancer and many more. Unfortunately, both dieting, exercise and current pharmacological intervention rarely meet the expectations of physicians and patients.

Our first-in-class therapeutic peptides are optimized analogues of an inhibitor of the GIP receptor that is found in the human body. They are designed for once-weekly self-administrable subcutaneous injection


Philip Just Larsen
CEO of 6 Peaks Bio with 20 years of experience leading research divisions within the pharmaceutical industry.
Prof. Jens Juul Holst
Discoverer of GLP-1, with over 1200 publications. The most cited living physiologist between 1996-2006.
Mark Currie
M.Sc., PhD
Ironwood BoD, inventor of linaclotide and built and led Ironwood R&D, Co-Founder and President of Cyclerion and inventor of multiple drugs in clinical dev. and currently serves as Chair of SAB
Jeroen Bakker
Principal at Novo Holdings
Has a broad background in VC, Corporate VC, and biotech consultancy.
Alexander H. Sparre-Ulrich
Chief Executive Officer
M.Sc. PhD
Award winning innovator that has led all commercialization and R&D activities since company inception.

Mads T. Christensen
Chief Scientific Officer
Former Corporate Vice President of Global Obesity and Liver Disease at Novo Nordisk

John Boland
Vice President, Clinical Operations
Over 20+ years of regulatory, strategic, and clinical operations experience within autonomic diseases

Robert Wallis
Head of Safety Pharmacology
M.Sc. PhD
Former Head of Global Safety Pharmacology at Pfizer.

Sandra C. Cottrell
Head of Regulatory Strategy
M.Sc. PhD
Over 35+ years of regulatory experience (JNJ, Novo Nordisk, NPS Pharm, Chugai, etc.)
Jakob Dynnes Hansen
Chief Financial Officer
M.Sc., MBA
Has more than 25 years of combined experience from biotech and financing.
Kaare G. Rasmussen
Head of Chemical Development
M.Sc. PhD
Has more than 20 years of CMC experience with a focus on drug manufacturing and project management
René Egebro
Head of Pharmaceutical Development
Has more than 20 years of CMC experience with a focus on drug product- and analytical development

Mette Høy Jensen
Director Scientific Affairs
M.Sc., Ph.D.
Has more than seven years of Biotech experience running preclinical and clinical studies


Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors

JULY 15, 2021

Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors.

Novo Seeds invests millions in diabetes venture with huge potential

JUNE 26, 2017

Denmark’s largest business newspaper (Børsen) covers Antag Therapeutic’s launch in this article

Novo Seeds invests millions in new venture

JUNE 26, 2017 covers the launch of Antag Therapeutics in the following article in Danish.